Beyond PSMA: A Dual-Target Radioligand Takes Aim at FAP and αvβ3

/in /by

Most radioligand therapies rely on a single molecular target. INN02 takes a different approach, combining two targets in the same molecule: fibroblast activation protein (FAP) and integrin αvβ3, both found in the tumour microenvironment. The same compound can be labelled with gallium-68 for PET imaging or lutetium-177 for therapy, creating a true theranostic platform. In […]

Read more

UPDATE: Aglatimagene Besadenovec (CAN-2409), Phase 3 Benefit Now Backed by Evidence of Lasting Immune Remodeling

/in , , /by

The story around aglatimagene besadenovec (CAN-2409) has become more interesting (we already talked about it in this article). The phase 3 PrTK03 trial had already shown that adding this locally injected viral immunotherapy to radiotherapy improved disease-free survival in men with intermediate- to high-risk localised prostate cancer. New biomarker data now provide a biological explanation […]

Read more

ATM-Altered Prostate Cancer May Be Especially Sensitive to Lu-177-PSMA

/in /by

A new study suggests that ATM alterations could identify a subgroup of metastatic castration-resistant prostate cancer particularly likely to benefit from 177Lu-PSMA-617 (Pluvicto). The retrospective analysis included 205 men with mCRPC treated with Lu-177-PSMA-617 between 2022 and 2026, all of whom had next-generation DNA sequencing available. ATM alterations were present in 12.7% of patients and […]

Read more

TTX-MC138 Takes Aim at a Master MicroRNA

/in /by

Most cancer drugs attack something on the tumour cell: a receptor, an enzyme, a signalling pathway or a surface protein. TTX-MC138 takes a different approach. It is designed to inhibit microRNA-10b (miR-10b), a small regulatory RNA strongly associated with invasion, metastatic progression and survival of metastatic tumour cells. The idea is unusually ambitious: rather than […]

Read more

Phase 2/3 Trial For 68Ga-DOTA-RM2: GRPR-Targeted PET Could Open the Door to a New Theranostic Platform

/in , , , , , , /by

PSMA has transformed prostate cancer imaging and radioligand therapy, but it is not the only useful target on prostate cancer cells. A new pivotal trial, SPARROW, is now testing 68Ga-DOTA-RM2, a PET tracer that targets the gastrin-releasing peptide receptor, or GRPR, in men with prostate cancer. The study is designed to determine how accurately GRPR-PET […]

Read more

Eight-Year PACE-A Results Support SBRT for Localised Prostate Cancer

/in , , /by

For men with localised low- or intermediate-risk prostate cancer who need treatment, one of the biggest decisions is whether to choose surgery or radiotherapy. The phase 3 PACE-A trial is the first randomised study to directly compare modern prostatectomy with stereotactic body radiotherapy (SBRT) delivered in just five treatments. New long-term results presented at ASTRO […]

Read more

Can We Predict Deep PSA Response Before Treatment Starts? NADIR Validated in ARCHES

/in , /by

A new analysis of the phase 3 ARCHES trial suggests that a simple clinical model may help predict which men with metastatic hormone-sensitive prostate cancer are most likely to achieve a very deep PSA response after starting treatment with an androgen-receptor pathway inhibitor. The model, called NADIR, was designed to estimate the probability of reaching […]

Read more

Carboplatin Shows Activity in HRR-Altered Metastatic Prostate Cancer

/in , , /by

Platinum chemotherapy is not usually considered a standard targeted treatment for metastatic prostate cancer, but the phase 2 CIPHER trial suggests that carboplatin may have meaningful activity in men with mCRPC carrying homologous recombination repair (HRR) mutations. The study enrolled 39 patients with HRR-altered mCRPC who had already received at least one androgen-receptor pathway inhibitor […]

Read more